Page 2 - Pharma Plc News Today

Redx Pharma Plc (LON:REDX – Get Free Report) insider Lisa Anson purchased 115,000 shares of the firm’s stock in a transaction on Tuesday, April 16th. The shares were acquired at an average cost of GBX 9 ($0.11) per share, with a total value of £10,350 ($12,884.35). Lisa Anson also recently made the following trade(s): On […]

Redx Pharma Plc (LON:REDX – Get Free Report)’s share price hit a new 52-week low during mid-day trading on Friday . The company traded as low as GBX 4 ($0.05) and last traded at GBX 4.30 ($0.05), with a volume of 8616193 shares. The stock had previously closed at GBX 7.50 ($0.09). Redx Pharma Price […]

Redx Pharma Plc (LON:REDX – Get Free Report)’s share price reached a new 52-week low during trading on Friday . The stock traded as low as GBX 4 ($0.05) and last traded at GBX 4.30 ($0.05), with a volume of 8616193 shares changing hands. The stock had previously closed at GBX 7.50 ($0.09). Redx Pharma […]

Shares of Redx Pharma Plc (LON:REDX – Get Free Report) hit a new 52-week low during trading on Wednesday . The stock traded as low as GBX 18 ($0.23) and last traded at GBX 19.20 ($0.24), with a volume of 121513 shares traded. The stock had previously closed at GBX 19.50 ($0.25). Redx Pharma Price […]

N4 Pharma Plc (LON:N4P – Get Free Report)’s share price reached a new 52-week low on Monday . The stock traded as low as GBX 0.70 ($0.01) and last traded at GBX 0.70 ($0.01), with a volume of 177605 shares. The stock had previously closed at GBX 0.78 ($0.01). N4 Pharma Stock Down 9.7 % […]

Shares of N4 Pharma Plc (LON:N4P – Get Free Report) hit a new 52-week low on Monday . The company traded as low as GBX 0.70 ($0.01) and last traded at GBX 0.70 ($0.01), with a volume of 177605 shares trading hands. The stock had previously closed at GBX 0.78 ($0.01). N4 Pharma Stock Performance […]

N4 Pharma Plc provides an update on its in vitro siRNA research work, showcasing the versatility of their Nuvec® delivery system for cancer treatments.

N4 Pharma Plc announces the granting of a patent for its Nuvec® delivery system in India, adding to its global portfolio of granted patents.

N4 Pharma's subsidiary, Nanogenics, has signed a contract to prepare its ECP105 product for pre-clinical studies in Glaucoma treatment.

/PRNewswire/ -- The human microbiome therapeutics market is expected to grow by USD 732.95 million from 2022 to 2027. In addition, the momentum of the market...